Turning the complexity
of a solid tumor against itself

Personalized, whole tumor-derived immunotherapies

Our science

Harnessing decades of research and multiple validated technologies, Imvax’s unique platform captures a tumor’s full antigen signature and uses it to stimulate the patient’s innate and adaptive immunity against remaining tumor cells

Our Pipeline

With promising clinical data in Glioblastoma and preclinical data in multiple other solid tumors, Imvax is developing a diverse pipeline of personalized, whole tumor-derived treatments